- Home
- TLSI vs WHG Comparison
TLSI vs WHG Comparison
Compare TLSI & WHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- WHG
- Stock Information
- Founded
- TLSI 2010
- WHG 1983
- Country
- TLSI United States
- WHG United States
- Employees
- TLSI N/A
- WHG N/A
- Industry
- TLSI Medical Specialities
- WHG Investment Managers
- Sector
- TLSI Health Care
- WHG Finance
- Exchange
- TLSI Nasdaq
- WHG Nasdaq
- Market Cap
- TLSI 124.9M
- WHG 148.5M
- IPO Year
- TLSI N/A
- WHG 2002
- Fundamental
- Price
- TLSI $3.95
- WHG $15.24
- Analyst Decision
- TLSI Strong Buy
- WHG
- Analyst Count
- TLSI 6
- WHG 0
- Target Price
- TLSI $11.75
- WHG N/A
- AVG Volume (30 Days)
- TLSI 52.7K
- WHG 17.1K
- Earning Date
- TLSI 11-14-2024
- WHG 02-12-2025
- Dividend Yield
- TLSI N/A
- WHG 3.97%
- EPS Growth
- TLSI N/A
- WHG N/A
- EPS
- TLSI N/A
- WHG 0.32
- Revenue
- TLSI $26,891,000.00
- WHG $92,368,000.00
- Revenue This Year
- TLSI $60.97
- WHG N/A
- Revenue Next Year
- TLSI $53.69
- WHG N/A
- P/E Ratio
- TLSI N/A
- WHG $47.75
- Revenue Growth
- TLSI 67.90
- WHG 6.16
- 52 Week Low
- TLSI $3.50
- WHG $11.00
- 52 Week High
- TLSI $10.42
- WHG $18.03
- Technical
- Relative Strength Index (RSI)
- TLSI 46.18
- WHG 45.07
- Support Level
- TLSI $3.76
- WHG $15.23
- Resistance Level
- TLSI $4.17
- WHG $15.79
- Average True Range (ATR)
- TLSI 0.35
- WHG 0.50
- MACD
- TLSI -0.04
- WHG -0.08
- Stochastic Oscillator
- TLSI 33.66
- WHG 23.78
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About WHG Westwood Holdings Group Inc
Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals, and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high-net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States.